RT @eastvillagetwt: #DCVaxL $NWBO “This article is in the 99th percentile (ranked 104th) of the 292,882 tracked articles of a similar age…
初発 膠芽腫 手術・放射線の後 ・TMZのみ ・TMZ+自家樹状細胞ワクチン を対照した第3相臨床試験の最初の結果 まだTotalの結果しか掲載してないもよう ツイートにその先の結果もある的なことが
RT @eastvillagetwt: $NWBO #DCVaxL Top Line Data Phase 3 pending #GBM #Glioblastoma #CancerVaccine for solid tumors Earlier Blinded Results…
$NWBO #DCVaxL Top Line Data Phase 3 pending #GBM #Glioblastoma #CancerVaccine for solid tumors Earlier Blinded Results: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
#DCVaxL $NWBO “This article is in the 99th percentile (ranked 104th) of the 292,882 tracked articles of a similar age in all journals and the 1st percentile (ranked 1st) of the 1 tracked articles of a similar age in Journal of Translational Medicine” ht
RT @Dave46217976: $NWBO #DCVAX
RT @sharpie510: "Yes, there are a number of clinical trials now that are showing what we've never seen in the field before is that a signif…
$NWBO #DCVAX
RT @sharpie510: "Yes, there are a number of clinical trials now that are showing what we've never seen in the field before is that a signif…
RT @sharpie510: "Yes, there are a number of clinical trials now that are showing what we've never seen in the field before is that a signif…
"Yes, there are a number of clinical trials now that are showing what we've never seen in the field before is that a significant percentage of patients are living 3 years, 5 years and beyond..." Dr. Brem co-authored the $nwbo JTM: https://t.co/ApO8HAV0Tq
RT @alphavestcap: @alphavestcap $nwbo WU/St Louis is a site in the 331 Dc Vaxl trial. https://t.co/jYYKzDbenU https://t.co/tUGKgIMQoD
@alphavestcap $nwbo WU/St Louis is a site in the 331 Dc Vaxl trial. https://t.co/jYYKzDbenU https://t.co/tUGKgIMQoD
RT @xnoxpx: @CarrieWilbur1 @JeremyLaszlo @MaxFromQuebec @DrTomFrieden The research on mRNA vaccines originated with developing treatments f…
You know what’s awesome? Watching the future of health science unfold in our lifetime.
@CarrieWilbur1 @JeremyLaszlo @MaxFromQuebec @DrTomFrieden The research on mRNA vaccines originated with developing treatments for cancer. We've got phase III trial results from 2018 that show they're safe. The future of vaccines is mRNA because it allows a
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma Linda M. Liau, Keyoumars Ashkan, […]Marnix L. Bosch https://t.co/PO8PPtUobH
RT @sharpie510: Immunotherapy is I think an ongoing area of interest in the treatment of glioma. -- Dr. Andrew Sloan Dr. Sloan is a co-aut…
Immunotherapy is I think an ongoing area of interest in the treatment of glioma. -- Dr. Andrew Sloan Dr. Sloan is a co-author on the Journal of Translational Medicine article on #DCVax-L for #glioblastoma. $nwbo $mrk $bmy $rhhby https://t.co/ApO8HAV0Tq
@ly17077576 This still doesn’t answer your question but offers a little more insight. If I am understanding correctly, 50% of the patients were enrolled between May ‘14 and Nov. ‘15. https://t.co/FRuppsPKYN https://t.co/TN4CorFOhX
@skaits1 @pjmagic1 @Biotech_SD Excellent DD to start with, $NWBO https://t.co/aymuygePTT https://t.co/tygF8hYRmx White paper from Carlo Rago
@Biotech2k1 @AuthorVenkatesh not that great?? you may want to reconsider... https://t.co/ZvSGZR44Wq
$NWBO Updated article. https://t.co/MDGTHJ04Av Thanks to Ihub community again for great info and quick update 💪🏻 Soon $3, $5, $10, $15, $20 ... and who knows.
RT @OrlyAlter: Friday 4/9, 11:45am MDT, join @UtahBME Bioengineering Elevated Lecture & discussion w/ students: Prof. Linda Liau, Chair #Ne…
@MedResCol @ATLnsider Bit of a difference in phase III results... NWBO phase III results: https://t.co/94Ya9uGjpU Argus phase III results: https://t.co/iuxG9DWTcd
"First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma." J. Transl. Med. 2018, 16, 142, doi:10.1186/s12967-018-1507-6. https://t.co/fE6c2sutlx
RT @ATLnsider: He didn’t know final results. Dr. Brem & the Hospital of the University of Penn participated in $NWBO #DCVax trial. Penn was…
RT @ATLnsider: He didn’t know final results. Dr. Brem & the Hospital of the University of Penn participated in $NWBO #DCVax trial. Penn was…
RT @ATLnsider: He didn’t know final results. Dr. Brem & the Hospital of the University of Penn participated in $NWBO #DCVax trial. Penn was…
RT @ATLnsider: He didn’t know final results. Dr. Brem & the Hospital of the University of Penn participated in $NWBO #DCVax trial. Penn was…
He didn’t know final results. Dr. Brem & the Hospital of the University of Penn participated in $NWBO #DCVax trial. Penn was a trial site & had patients in the trial. Dr. Brem was also 1 of the authors of the DCVax-L interim study results released
RT @sharpie510: Dr. Charles S. Cobbs, one of the course chairs, is also familiar with DCVax-L. He's one of the co-authors of the Journal of…
RT @sharpie510: Dr. Charles S. Cobbs, one of the course chairs, is also familiar with DCVax-L. He's one of the co-authors of the Journal of…
Dr. Charles S. Cobbs, one of the course chairs, is also familiar with DCVax-L. He's one of the co-authors of the Journal of Translational Medicine article on the blinded results. $nwbo #dcvax #glioblastoma https://t.co/ApO8HAV0Tq
@Ahmad_B_Mahmoud Interesting approach. Dendritic cell vaccination is another promising technology. DCVax-L Phase III unblinded data will be published very soon. Here is the blinded data from 2018👇🏼 https://t.co/QuYnWq8rGQ
If anyone is doubting their belief in their hold of $NWBO, just read this -- undoubtedly some of the best content out there: https://t.co/wPRp0Z8pa9 AND https://t.co/o6Ps1hfSpc
@MedResCol @trollntung @sanderhamburger Yes, everyone should read this and come to their own conclusions. Even blinded data blows away current standard of care, and has no side effects. https://t.co/qONmtCvbtN
RT @eastvillagetwt: @legalsagecom @MedResCol A medical journal, or or the above described MRC First results on survival from a large Phas…
RT @eastvillagetwt: @legalsagecom @MedResCol A medical journal, or or the above described MRC First results on survival from a large Phas…
@legalsagecom @MedResCol A medical journal, or or the above described MRC First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma | Journal of Translational Medicine | Full Tex
RT @griffin8210: My BIO -runners today $NWBO $AMPE
RT @griffin8210: My BIO -runners today $NWBO $AMPE
My BIO -runners today $NWBO $AMPE
RT @sharpie510: Jessica Morris is a 4.5 year #glioblastoma survivor. She is lucky her doctor was Dr. Fabio Iwamoto. He's on the $NWBO #DCVa…
RT @sharpie510: Jessica Morris is a 4.5 year #glioblastoma survivor. She is lucky her doctor was Dr. Fabio Iwamoto. He's on the $NWBO #DCVa…
RT @sharpie510: Jessica Morris is a 4.5 year #glioblastoma survivor. She is lucky her doctor was Dr. Fabio Iwamoto. He's on the $NWBO #DCVa…
RT @sharpie510: Jessica Morris is a 4.5 year #glioblastoma survivor. She is lucky her doctor was Dr. Fabio Iwamoto. He's on the $NWBO #DCVa…
RT @sharpie510: Jessica Morris is a 4.5 year #glioblastoma survivor. She is lucky her doctor was Dr. Fabio Iwamoto. He's on the $NWBO #DCVa…
RT @sharpie510: Jessica Morris is a 4.5 year #glioblastoma survivor. She is lucky her doctor was Dr. Fabio Iwamoto. He's on the $NWBO #DCVa…
Jessica Morris is a 4.5 year #glioblastoma survivor. She is lucky her doctor was Dr. Fabio Iwamoto. He's on the $NWBO #DCVax-L Steering Committee and co-author of the JTM article on the phase 3 clinical trial. $mrk $bmy @JoeBiden https://t.co/frxPI0GqgX
@navynotnuclear @InRhodesLtd @LeedsNeuro @harshanmurthy @Leeds_Neurosurg @DanielWalshFRCS Hello, try looking here:https://t.co/LOJZG5SDu4 & https://t.co/t1eGQSKxJk & https://t.co/IxCIl9LrmW & https://t.co/wRrZKkzCXX. Final Results from the Pha
للاستزادة ومعلومات أكثر: موقع الشركة https://t.co/NRmCUwLd6G آخر ورقة علمية نشرت لهم https://t.co/QuYnWq8rGQ
RT @sharpie510: Looking forward to this #glioblastoma webinar tomorrow. Dr. Duma is 1 of the 69 co-authors on the DCVax-L JTM publication.…
RT @sharpie510: Looking forward to this #glioblastoma webinar tomorrow. Dr. Duma is 1 of the 69 co-authors on the DCVax-L JTM publication.…
RT @sharpie510: Looking forward to this #glioblastoma webinar tomorrow. Dr. Duma is 1 of the 69 co-authors on the DCVax-L JTM publication.…
RT @sharpie510: Looking forward to this #glioblastoma webinar tomorrow. Dr. Duma is 1 of the 69 co-authors on the DCVax-L JTM publication.…
Looking forward to this #glioblastoma webinar tomorrow. Dr. Duma is 1 of the 69 co-authors on the DCVax-L JTM publication. https://t.co/frxPI0GqgX $nwbo #dcvax $mrk $bmy #gbm #cancer #vaccine
@rago_carlo Took another look at the 10K and the blinded interim publication: https://t.co/9GkTIUI9gv Chances are that the science works. What most people miss is that DCVAX has applications to more tumor types than just GBM. Patents are good till 2022-20
RT @rago_carlo: @AndyBiotech $NWBO DCVax-L Phase 3 GBM data lock coming in June with top line in July, per company. Autologous dendritic ce…
RT @rago_carlo: @AndyBiotech $NWBO DCVax-L Phase 3 GBM data lock coming in June with top line in July, per company. Autologous dendritic ce…
RT @rago_carlo: @AndyBiotech $NWBO DCVax-L Phase 3 GBM data lock coming in June with top line in July, per company. Autologous dendritic ce…
@AndyBiotech $NWBO DCVax-L Phase 3 GBM data lock coming in June with top line in July, per company. Autologous dendritic cell vaccine from tumor lysate, i.e. all the antigens. Compelling interim results. https://t.co/2YXWpw4z8N
RT @sentimentstock: @matthewherper It's laughable how both of you approached handling this leak on $GILD's resdimiver last week (especially…
@matthewherper It's laughable how both of you approached handling this leak on $GILD's resdimiver last week (especially w/this latest WHO leak), and yet you pinch your noses and make the sign of the cross to $NWBO's 1st results to their blinded (not for lo
@justinkeister5 @patrickwalsh14 @rago_carlo I stand corrected it was 5 weeks. https://t.co/yDEIEF7pTr No we were told it was submitted and that's the story we got feed. I never doubted the science, I doubt the management and the lies they continue to spe
RT @rago_carlo: @MedResCol @SchlangDaddy @ColemanCullen @sharpie510 @biggercapital @Scribd This is from the Liau/Bosch publication of the $…
@MedResCol @SchlangDaddy @ColemanCullen @sharpie510 @biggercapital @Scribd This is from the Liau/Bosch publication of the $NWBO #DCVax #GBM interim clinical trial data, suggesting that your assertion is absolutely incorrect. https://t.co/2YXWpw4z8N https:
RT @LilianeM8: @mnsarkis هو من اصعب انواع الكانسر بس في تجارب عم بتصير بأميركا https://t.co/WgKC1f0DC3
@mnsarkis هو من اصعب انواع الكانسر بس في تجارب عم بتصير بأميركا https://t.co/WgKC1f0DC3
RT @sharpie510: Dr. Michael Salacz is one of the co-authors on the interim blinded results for #DCVax-L: https://t.co/frxPI0GqgX He's conf…
RT @sharpie510: Dr. Michael Salacz is one of the co-authors on the interim blinded results for #DCVax-L: https://t.co/frxPI0GqgX He's conf…
RT @sharpie510: Dr. Michael Salacz is one of the co-authors on the interim blinded results for #DCVax-L: https://t.co/frxPI0GqgX He's conf…
Dr. Michael Salacz is one of the co-authors on the interim blinded results for #DCVax-L: https://t.co/frxPI0GqgX He's confident about improving survival & qol in #gbm. I think we all know what he's talking about! $nwbo #glioblastoma https://t.co/jkif
@Susan12409 @tweetmommybop This is a screenshot of the indication that there is a segment of the population that lives much longer with the vaccine. Source: https://t.co/IxCIl9tQvo https://t.co/VD93TATMAD
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. https://t.co/uO2ROeEeSU
@james_peters55 @biggercapital First: Both the company (in at least one press release) and the recent interim publication (linked below) note that progression free survival was the primary outcome and overall survival was the secondary outcome. $NWBO #DCVa
The words “may extend survival” are key. Many did not survive so still far from a cure. As I said there’ll always be positive outliers who’d survive on pretty much anything and then claim great success. Evidence of real success for the many needed #curenow
@BrianRockell Here is a link to the evidence... https://t.co/VFg1Kx5YSf
Recent Results: https://t.co/IxCIl9LrmW Mesenchymal: https://t.co/hC7XPfIGNE "Microarray gene-expression profiling revealed that Jones and the others in his trial who are still alive had tumors with mesenchymal gene-expression signatures."
I’m going to read that. But the English major in me is cringing at “their” instead of “there.” :-{ Let me read this link. Thank you :)
C) @JohnMayerAsASim treated with success with keytruda. A combo of vaccine success, with those patients falling in the mesenchymal group may indicate that their is a combo therapy that can produce even more long term survivors. https://t.co/3Dp5lzywTx htt
RT @ChrisLacoursier: #CNBC #WSJ #Bloomberg investors #biotech should realize @NorthwestBio $NWBO preliminary blended P3 data has greater su…
@KateOfTheDebate I post incase a 2nd surgery is in the works,. I can tell you that the phase 3 clinical trial was a success, with 100 long term survivors out of 300,. The trial is waiting to be unblinded so more than just topline data can be published. htt
@AmandaHaddock @bryceolson Prt 1: Thank you for this opportunity. An article from Journal of Translational Medecine this summer: "A population of extended survivors (n = 100) with mOS of 40.5 months, not explained by known prognostic factors, will be anal
RT @NIHBrainTumor: *Corrected: Our neuro-oncology journal club includes point and counterpoint discussions on published research. Today, Dr…
Impressive!
RT @herkyleese: altmetric # -quality and quantity of attention an academic article has. https://t.co/FnnKvQbDDC just a few months = altme…
altmetric # -quality and quantity of attention an academic article has. https://t.co/FnnKvQbDDC just a few months = altmetric rating of 1414 The 100th academic article in 2017 rated at 1891 - many months remain 2018 #dcvax $nwbo #biotech Red =mainstream
RT @NIHBrainTumor: First results on survival from a large phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed…
First results on survival from a large phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. Liau et al., J. Transl. Med 2018 (UCLA) https://t.co/dTk7FsRuDP
@Tsarmstrong01 For people tuning in, you can read this first study here: https://t.co/dTk7FsRuDP Title and citation: First results on survival from a large phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. Li
RT @Christi90092509: A promising study published in Journal of Translational Medicine (May 2018), suggests an autologous tumor lysate-pulse…
A promising study published in Journal of Translational Medicine (May 2018), suggests an autologous tumor lysate-pulsed dendritic cell vaccine (DCVax-L) could prolong the lives of glioblastoma patients https://t.co/Uuop1MNcCa #BrainyTigers #bio4500
A new vaccine is unblinding it's phase 3 results any day. Preliminary results point to long term survivors in mesenchymal subgroup. https://t.co/IxCIl9tQvo. Vaccine is made from tumor tissue saved from surgery. No harm in saving tissue if you want to purs